New Huntington's drug enters first human safety trial
NCT ID NCT07536061
First seen Apr 19, 2026 · Last updated May 21, 2026 · Updated 4 times
Summary
This early-stage trial tests a new drug called SRP-1005 in 32 adults with Huntington's disease. The main goal is to check safety and side effects, not to cure the disease. Participants must have a confirmed genetic diagnosis and be in early to mild stages of the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New Zealand Brain Research Institute
Christchurch, 8014, New Zealand
-
Pacific Clinical Research Network - Auckland (PCRN Auckland)
Auckland, 622, New Zealand
Conditions
Explore the condition pages connected to this study.